Q4 Earnings Estimate for NAMS Issued By Leerink Partnrs

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities researchers at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for NewAmsterdam Pharma in a note issued to investors on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will earn ($0.35) per share for the quarter. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma's FY2028 earnings at $0.42 EPS.

A number of other brokerages also recently issued reports on NAMS. Royal Bank of Canada reissued an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Needham & Company LLC reissued a "buy" rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, December 11th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Six analysts have rated the stock with a buy rating, According to MarketBeat, NewAmsterdam Pharma currently has a consensus rating of "Buy" and a consensus target price of $36.20.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded down $0.43 on Thursday, reaching $25.46. The company's stock had a trading volume of 660,529 shares, compared to its average volume of 376,012. NewAmsterdam Pharma has a 12-month low of $10.29 and a 12-month high of $27.29. The stock has a 50 day moving average price of $21.16 and a 200 day moving average price of $18.90.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Banque Cantonale Vaudoise acquired a new stake in NewAmsterdam Pharma in the second quarter valued at approximately $38,000. Quarry LP increased its position in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC raised its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth $128,000. Finally, XTX Topco Ltd purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth $187,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insiders Place Their Bets

In related news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29. Following the completion of the transaction, the insider now directly owns 11,150,461 shares in the company, valued at approximately $283,110,204.79. This trade represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 45,000 shares of the company's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The disclosure for this sale can be found here. Insiders have sold 252,814 shares of company stock worth $5,970,327 over the last three months. Company insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.